Pietro Sollena

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Journal: Acta dermato-venereologica

Published: January 09, 2026

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Journal: Acta dermato-venereologica

Published: January 09, 2026

Dermatologic adverse events associated with amivantamab: A multicentre study.

Dermatologic adverse events associated with amivantamab: A multicentre study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 05, 2025

Dermatological adverse events during hematological and oncological therapies (Bruton's tyrosine kinase inhibitors and mogamulizumab): an Italian retrospective multicenter study.

Dermatological adverse events during hematological and oncological therapies (Bruton's tyrosine kinase inhibitors and mogamulizumab): an Italian retrospective multicenter study.

Journal: Italian journal of dermatology and venereology

Published: October 03, 2025

Granuloma faciale-like eruption associated with mogamulizumab treatment.

Granuloma faciale-like eruption associated with mogamulizumab treatment.

Journal: Italian journal of dermatology and venereology

Published: September 24, 2025

Topical Ruxolitinib as an Effective Therapy for Vitiligo-Like Lesions Induced by Anti-PD-1 Therapy.

Topical Ruxolitinib as an Effective Therapy for Vitiligo-Like Lesions Induced by Anti-PD-1 Therapy.

Journal: International journal of dermatology

Published: July 01, 2025

Dupilumab for immune checkpoint inhibitors-induced pruritic dermatoses: A retrospective, multicentric study.

Dupilumab for immune checkpoint inhibitors-induced pruritic dermatoses: A retrospective, multicentric study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 01, 2025

Immune Checkpoint Inhibitor-Induced Lipodystrophy.

Immune Checkpoint Inhibitor-Induced Lipodystrophy.

Journal: JAMA dermatology

Published: April 09, 2025

Prevention and management of cutaneous immune-related adverse events: EADV Task Force statement.

Prevention and management of cutaneous immune-related adverse events: EADV Task Force statement.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 04, 2025

Challenging Reconstruction of a Large Cheek Defect.

Challenging Reconstruction of a Large Cheek Defect.

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Published: March 19, 2025

Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.

Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.

Journal: JAMA dermatology

Published: December 23, 2024

Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of 'Dermatology for Cancer Patients'.

Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of 'Dermatology for Cancer Patients'.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 17, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026